Neovasc (TSX:NVCN) EV-to-EBIT : -1.81 (As of May. 12, 2024)

View and export this data going back to 2001. Start your Free Trial

What is Neovasc EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Neovasc's Enterprise Value is C$94.48 Mil. Neovasc's EBIT for the trailing twelve months (TTM) ended in Dec. 2022 was C$-52.11 Mil. Therefore, Neovasc's EV-to-EBIT for today is -1.81.

The historical rank and industry rank for Neovasc's EV-to-EBIT or its related term are showing as below:

TSX:NVCN' s EV-to-EBIT Range Over the Past 10 Years
Min: -434.16 Med: -1.5 Max: 0.86
Current: -1.79

During the past 13 years, the highest EV-to-EBIT of Neovasc was 0.86. The lowest was -434.16. And the median was -1.50.

TSX:NVCN's EV-to-EBIT is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 20.82 vs TSX:NVCN: -1.79

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Neovasc's Enterprise Value for the quarter that ended in Dec. 2022 was C$41.51 Mil. Neovasc's EBIT for the trailing twelve months (TTM) ended in Dec. 2022 was C$-52.11 Mil. Neovasc's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2022 was -125.54%.

Neovasc EV-to-EBIT Historical Data

The historical data trend for Neovasc's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neovasc EV-to-EBIT Chart

Neovasc Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EV-to-EBIT

Get a 7-Day Free Trial

-0.21

-1.64

-0.82

0.45

-0.77

Neovasc Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
EV-to-EBIT	Get a 7-Day Free Trial															0.45	0.07	0.27	-	-0.77

Competitive Comparison of Neovasc's EV-to-EBIT

For the Medical Devices subindustry, Neovasc's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neovasc's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Neovasc's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Neovasc's EV-to-EBIT falls into.

Neovasc EV-to-EBIT Calculation

Neovasc's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	94.480	/	-52.109
	=	-1.81

Neovasc's current Enterprise Value is C$94.48 Mil.
Neovasc's EBIT for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-52.11 Mil.

Neovasc (TSX:NVCN) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Neovasc's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2022 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2022 )	=	EBIT	/	Enterprise Value (Q: Dec. 2022 )
	=	-52.109	/	41.5063812
	=	-125.54 %

Neovasc's Enterprise Value for the quarter that ended in Dec. 2022 was C$41.51 Mil.
Neovasc's EBIT for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-52.11 Mil.

Neovasc EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Neovasc's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Neovasc (TSX:NVCN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Neovasc Inc (TSX:NVCN) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

13562 Maycrest Way, Suite 5138, Richmond, BC, CAN, V6V 2J7

Website

https://www.neovasc.com

Neovasc Inc is a specialty medical device company. It develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products the Neovasc Reducer (Reducer), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara, for the transcatheter treatment of mitral valve disease, which is under clinical investigation in the United States, Canada, Israel and Europe. The company earns revenue from one source, the Reducer.